Frontiers in Cellular and Infection Microbiology (Jun 2021)
The Safety, Immunogenicity, and Immunopersistence of Hepatitis A Vaccine in HBs-Ag-Positive Participants: A Retrospective Study
- Xiaodan Wang,
- Xiaodan Wang,
- Xiaodan Wang,
- Jia Luo,
- Jia Luo,
- Jia Luo,
- Fubao Ma,
- Guodong Kang,
- Zhengrong Ding,
- Yue Pan,
- Yue Pan,
- Yue Pan,
- Yujiao Zhao,
- Yujiao Zhao,
- Yujiao Zhao,
- Junying Chen,
- Junying Chen,
- Junying Chen,
- Kai Feng,
- Kai Feng,
- Kai Feng,
- Lingmei Yan,
- Lingmei Yan,
- Lingmei Yan,
- Juan Zhang,
- Juan Zhang,
- Juan Zhang,
- Juan Zhang,
- Linhao Li,
- Linhao Li,
- Linhao Li,
- Linhao Li,
- Qiangping Lan,
- Qiangping Lan,
- Qiangping Lan,
- Daiying Li,
- Daiying Li,
- Daiying Li,
- Xiaolei Yang,
- Xiaolei Yang,
- Xiaolei Yang,
- Guoliang Li,
- Guoliang Li,
- Guoliang Li,
- Jingsi Yang,
- Jingsi Yang,
- Jingsi Yang,
- Qiangming Sun,
- Qiangming Sun,
- Qiangming Sun
Affiliations
- Xiaodan Wang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Xiaodan Wang
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Xiaodan Wang
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Jia Luo
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Jia Luo
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Jia Luo
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Fubao Ma
- Vaccines and Immunization Department, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, China
- Guodong Kang
- Vaccines and Immunization Department, Jiangsu Provincial Center of Disease Control and Prevention, Nanjing, China
- Zhengrong Ding
- Vaccines and Immunization Department, Yunnan Provincial Center of Disease Control and Prevention, Kunming, China
- Yue Pan
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Yue Pan
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Yue Pan
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Yujiao Zhao
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Yujiao Zhao
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Yujiao Zhao
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Junying Chen
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Junying Chen
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Junying Chen
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Kai Feng
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Kai Feng
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Kai Feng
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Lingmei Yan
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Lingmei Yan
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Lingmei Yan
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Juan Zhang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Juan Zhang
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Juan Zhang
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Juan Zhang
- School of Basic Medicine, Kunming Medical University, Kunming, China
- Linhao Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Linhao Li
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Linhao Li
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Linhao Li
- School of Basic Medicine, Kunming Medical University, Kunming, China
- Qiangping Lan
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Qiangping Lan
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Qiangping Lan
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Daiying Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Daiying Li
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Daiying Li
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Xiaolei Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Xiaolei Yang
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Xiaolei Yang
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Guoliang Li
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Guoliang Li
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Guoliang Li
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Jingsi Yang
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Jingsi Yang
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Jingsi Yang
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- Qiangming Sun
- Institute of Medical Biology, Chinese Academy of Medical Sciences, and Peking Union Medical College, Kunming, China
- Qiangming Sun
- Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming, China
- Qiangming Sun
- Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Kunming, China
- DOI
- https://doi.org/10.3389/fcimb.2021.672221
- Journal volume & issue
-
Vol. 11
Abstract
ObjectivesTo compare the safety, immunogenicity, and immune persistence of hepatitis A (HA) vaccines between HBs-Ag-positive and -negative participants.Method9000 participants were enrolled in the phase IV study of live attenuated HA (HA-L) or inactivated HA (HA-I) vaccines. The HBs-Ag-positive subjects were detected and became an independent observation group. Adverse reactions (ARs), geometric mean concentrations (GMCs) and seroconversion rates (SRs) of the vaccines were analyzed at five time points until three years after vaccination. Results: 120 HBs-Ag-positive subjects were screened out, only 1 participant had grade 1 experienced ARs after HA-L injection. Except the time point of two years, the SRs of HBs-Ag-positive group were 100% for both vaccines. The GMCs were not statistically different between HBs-Ag-positive and -negative groups after the HA-L vaccination. The logarithmically transformed GMCs for HBs-Ag-positive and -negative groups were 3.21 mIU/mL (95% CI, 2.03-4.39 mIU/mL) and 2.95 mIU/mL (95% CI, 2.88-3.02 mIU/mL) 28 days after the HA-L vaccination, respectively.ConclusionsBoth HA-L and HA-I vaccines were safe for HBs-Ag-positive participants and may provide an excellent long-term protection against HAV in this study. The results indicated that people positive or negative for HBs-Ag can receive both HA-L and HA-I vaccines (ClinicalTrials.gov number, NCT02601040).
Keywords
